AZM: Azithromycin; ERY: Erythromycin; NA: Not applicable; ND: Not determined. Mycoplasma pneumoniae is a common cause of upper and lower respiratory tract infections in children and young adults.

erythromycin. It works by interfering with a bacterium's ability to produce proteins, thus inhibiting growth. Azithromycin is available as a tablet or liquid to be taken orally, an injectable ...

Long-term prophylactic azithromycin likely reduces the exacerbation frequency of children with bronchiectasis, and might improve the lung function. However, prolonged use increases antimicrobial ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

‡ NA: Macrolide resistance was determined by PCR directly from M. pneumoniae-positive samples; no resistant strain was isolated to be studied for in vitro susceptibility testing. AZM ...

Four of these trials were new for the 2024 update, adding just over 500 participants. All 14 trials looked at the effects of azithromycin. Six enrolled only children, one enrolled only adults and ...